[go: up one dir, main page]

MX2016013849A - Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. - Google Patents

Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.

Info

Publication number
MX2016013849A
MX2016013849A MX2016013849A MX2016013849A MX2016013849A MX 2016013849 A MX2016013849 A MX 2016013849A MX 2016013849 A MX2016013849 A MX 2016013849A MX 2016013849 A MX2016013849 A MX 2016013849A MX 2016013849 A MX2016013849 A MX 2016013849A
Authority
MX
Mexico
Prior art keywords
protein secretion
secretora
understands
secretion factor
expression vector
Prior art date
Application number
MX2016013849A
Other languages
English (en)
Other versions
MX383969B (es
Inventor
Chul Kim Yeon
Hae KIM Seung
Jung Saem
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MX2016013849A publication Critical patent/MX2016013849A/es
Publication of MX383969B publication Critical patent/MX383969B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un nuevo factor de secreción de proteínas, a un vector que incluye una secuencia de ácidos nucleicos que codifica el factor de secreción de proteínas y a una célula transformada en la cual es introducido el vector. La invención también se refiere a un procedimiento para producir una proteína diana usando le célula transformada que incluye el vector.
MX2016013849A 2014-04-30 2015-04-30 Un factor de secreción de proteínas con alta eficacia secretora y un vector de expresión que lo comprende. MX383969B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140052752A KR102092225B1 (ko) 2014-04-30 2014-04-30 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
PCT/KR2015/004389 WO2015167278A1 (en) 2014-04-30 2015-04-30 A protein secretory factor with high secretory efficiency and an expression vector comprising the same

Publications (2)

Publication Number Publication Date
MX2016013849A true MX2016013849A (es) 2017-02-02
MX383969B MX383969B (es) 2025-03-14

Family

ID=54358915

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013849A MX383969B (es) 2014-04-30 2015-04-30 Un factor de secreción de proteínas con alta eficacia secretora y un vector de expresión que lo comprende.
MX2020003508A MX2020003508A (es) 2014-04-30 2016-10-21 Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003508A MX2020003508A (es) 2014-04-30 2016-10-21 Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.

Country Status (10)

Country Link
US (3) US10407475B2 (es)
EP (1) EP3137493B1 (es)
JP (2) JP6471175B2 (es)
KR (1) KR102092225B1 (es)
CN (1) CN106255700B (es)
AR (1) AR100255A1 (es)
BR (1) BR112016024895A2 (es)
MX (2) MX383969B (es)
TW (1) TWI708780B (es)
WO (1) WO2015167278A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019083794A1 (en) 2017-10-27 2019-05-02 Pfenex Inc. PROCESS FOR PRODUCING EAR ASPARAGINASE. RECOMBINED COLI
AU2018354069A1 (en) * 2017-10-27 2020-06-11 Pelican Technology Holdings, Inc. Bacterial leader sequences for periplasmic protein expression
AU2018354067B2 (en) 2017-10-27 2023-03-30 Pfenex Inc. Method for production of recombinant Erwinia asparaginase
JP2021535746A (ja) 2018-09-05 2021-12-23 エルジー・ケム・リミテッド Ｏ−グリコシル化可能なポリペプチド領域を含む融合ポリペプチド
EP3893870A1 (en) 2018-12-13 2021-10-20 Huya Bioscience International LLC Sulcardine administration for treatment of acute atrial fibrillation
JP7253773B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
TW202337914A (zh) 2019-04-23 2023-10-01 南韓商Ｌｇ化學股份有限公司 融合多肽及其用途與製備方法、核酸分子、重組載體、重組細胞以及用於增強生長/分化因子15或其功能變體的活體內穩定性的方法
CN114761418B (zh) * 2019-12-02 2025-04-29 株式会社Lg化学 Cho细胞衍生的蛋白分泌因子和包含它的表达载体
CN117042805A (zh) 2021-04-05 2023-11-10 株式会社Lg化学 对抗冠状病毒的疫苗组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022847A (en) * 1997-03-19 2000-02-08 Zymogenetics, Inc. Secreted salivary zsig32 polypeptides
AU764441B2 (en) * 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
EP1666491A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20030062854A (ko) 2002-01-21 2003-07-28 주식회사 엘지생명과학 분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004094589A2 (en) 2003-04-18 2004-11-04 Incyte Corporation Secreted proteins
KR20070009269A (ko) * 2005-07-15 2007-01-18 한국생명공학연구원 재조합단백질 생산용 단백질융합인자 라이브러리 및이로부터 획득된 단백질융합인자
JP2007209328A (ja) 2006-01-13 2007-08-23 Galpharma Co Ltd ガレクチン−９利用遺伝子治療剤
KR100954322B1 (ko) * 2006-06-14 2010-04-21 주식회사 엘지생명과학 췌장암과 관련된 신규한 ｌｂｆｌ313 유전자
CN1903876B (zh) 2006-07-10 2010-09-01 郑鸿 一种多肽、编码它的核酸分子及用途
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
KR101868139B1 (ko) 2010-11-30 2018-06-15 주식회사 엘지화학 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
SG11201502816YA (en) 2012-10-12 2015-05-28 Agency Science Tech & Res Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics

Also Published As

Publication number Publication date
TW201625665A (zh) 2016-07-16
US20200255485A1 (en) 2020-08-13
US20230212236A1 (en) 2023-07-06
MX2020003508A (es) 2020-07-22
WO2015167278A1 (en) 2015-11-05
EP3137493A1 (en) 2017-03-08
JP2019006823A (ja) 2019-01-17
JP6471175B2 (ja) 2019-02-13
EP3137493A4 (en) 2017-11-15
EP3137493B1 (en) 2019-09-04
KR20150125402A (ko) 2015-11-09
BR112016024895A2 (pt) 2017-10-24
MX383969B (es) 2025-03-14
JP2017513511A (ja) 2017-06-01
CN106255700A (zh) 2016-12-21
US10407475B2 (en) 2019-09-10
CN106255700B (zh) 2021-06-18
KR102092225B1 (ko) 2020-03-23
TWI708780B (zh) 2020-11-01
US20170044224A1 (en) 2017-02-16
AR100255A1 (es) 2016-09-21

Similar Documents

Publication Publication Date Title
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EP3741848A3 (en) Protease variants and polynucleotides encoding same
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
DOP2018000181A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
GT201700048A (es) Terapias de combinación con anticuerpos anti-cd38
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
MX2017001556A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EP3201757A4 (en) Identifying temporal demand for autocomplete search results
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX381592B (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
MX369645B (es) Anticuerpos multiespecificos.
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
PH12017501815A1 (en) Humanized anti-c1s antibodies and methods of use thereof
IN2014MU01248A (es)
BR112017004495A2 (pt) variantes de celobiohidrolase e polinucleotídeos codificando as mesmas
MX2016008778A (es) Deteccion de acidos nucleicos de entamoeba.
MX2017010901A (es) Colorantes de acido trisazo.
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico